Peter Andersen Selected Research

Tuberculosis (Tuberculoses)

11/2021	A Mycobacterium tuberculosis-specific subunit vaccine that provides synergistic immunity upon co-administration with Bacillus Calmette-Guérin.
2/2021	In vivo antigen expression regulates CD4 T cell differentiation and vaccine efficacy against Mycobacterium tuberculosis infection.
1/2021	In Vivo Antigen Expression Regulates CD4 T Cell Differentiation and Vaccine Efficacy against Mycobacterium tuberculosis Infection.
10/2020	Immunization with Mycobacterium tuberculosis-Specific Antigens Bypasses T Cell Differentiation from Prior Bacillus Calmette-Guérin Vaccination and Improves Protection in Mice.
1/2020	CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent M. tuberculosis infection.
1/2020	Rescuing ESAT-6 Specific CD4 T Cells From Terminal Differentiation Is Critical for Long-Term Control of Murine Mtb Infection.
1/2020	Intrapulmonary (i.pulmon.) Pull Immunization With the Tuberculosis Subunit Vaccine Candidate H56/CAF01 After Intramuscular (i.m.) Priming Elicits a Distinct Innate Myeloid Response and Activation of Antigen-Presenting Cells Than i.m. or i.pulmon. Prime Immunization Alone.
1/2020	Diagnostic Accuracy of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Tuberculosis.
11/2019	Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles.
10/2019	Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Andersen Research Topics

Disease

111	Tuberculosis (Tuberculoses) 11/2021 - 02/2002
101	Infections 02/2021 - 06/2002
11	Neoplasms (Cancer) 12/2022 - 10/2007
8	Squamous Cell Carcinoma of Head and Neck 12/2022 - 05/2006
8	Latent Tuberculosis 01/2020 - 04/2003
7	Pulmonary Tuberculosis 01/2018 - 02/2002
7	Human Influenza (Influenza) 01/2018 - 09/2008
7	Latent Infection 01/2017 - 06/2004
4	Pain (Aches) 01/2022 - 01/2017
4	Necrosis 01/2021 - 01/2010
4	Inflammation (Inflammations) 01/2020 - 11/2009
4	Persistent Infection 01/2020 - 04/2014
4	Bovine Tuberculosis 10/2009 - 07/2003
3	Parasitic Diseases (Parasitic Disease) 01/2017 - 06/2012
3	Malaria 01/2017 - 09/2008
3	Reproductive Tract Infections 09/2015 - 04/2012
3	Melanoma (Melanoma, Malignant) 11/2014 - 01/2008
2	Opioid-Related Disorders (Opiate Addiction) 01/2022 - 11/2018
2	Bites and Stings (Sting) 01/2021 - 03/2016
2	Sarcopenia 01/2020 - 12/2017
2	Disease Progression 01/2020 - 02/2013
2	Wounds and Injuries (Trauma) 12/2019 - 12/2017
2	Chronic Hepatitis C 10/2019 - 01/2017
2	Postoperative Pain 11/2018 - 11/2017
2	Weight Loss (Weight Reduction) 11/2017 - 08/2011
2	Cardiomyopathies (Cardiomyopathy) 10/2017 - 04/2016
2	Hemorrhage 01/2017 - 11/2013
2	Fever (Fevers) 01/2017 - 01/2017
2	Communicable Diseases (Infectious Diseases) 05/2015 - 05/2010
2	Poliomyelitis (Polio) 04/2015 - 01/2014
2	Chlamydia Infections 02/2014 - 04/2012
2	Head and Neck Neoplasms (Head and Neck Cancer) 11/2013 - 06/2012
2	Hypersensitivity (Allergy) 04/2008 - 08/2003
1	Muscular Diseases (Myopathy) 01/2022
1	Headache Disorders (Headache Syndromes) 01/2022
1	Headache (Headaches) 01/2022
1	COVID-19 01/2021

Drug/Important Bio-Agent (IBA)

88	VaccinesIBA 02/2021 - 05/2002
55	AntigensIBA 02/2021 - 02/2002
38	Proteins (Proteins, Gene)FDA Link 01/2020 - 07/2002
25	Subunit VaccinesIBA 11/2021 - 06/2002
24	Tuberculin (PPD)IBA 01/2020 - 04/2003
15	AerosolsIBA 02/2021 - 06/2002
13	Interferon-gamma (Interferon, gamma)IBA 01/2020 - 11/2003
12	CytokinesIBA 10/2019 - 06/2004
11	BCG Vaccine FDA Link 10/2020 - 02/2002
11	Liposomes (Liposome)IBA 01/2017 - 03/2007
10	Peptides (Polypeptides)IBA 01/2021 - 07/2002
9	EpitopesIBA 01/2017 - 12/2006
7	Indicators and Reagents (Reagents)IBA 06/2013 - 02/2002
6	Immunoglobulin A (IgA)IBA 01/2020 - 01/2011
6	Immunoglobulin G (IgG)IBA 04/2017 - 05/2004
6	AntibodiesIBA 01/2017 - 01/2005
5	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2006
5	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 06/2012
5	LipidsIBA 01/2020 - 10/2004
5	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2012 - 07/2007
5	Interleukin-4 (Interleukin 4)IBA 01/2012 - 06/2004
4	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 01/2017 - 06/2004
4	Interleukin-2 (IL2)IBA 01/2013 - 07/2007
3	bis(p-chlorophenyl)acetic acid (DDA)IBA 01/2021 - 01/2010
3	Interleukin-17 (Interleukin 17)IBA 01/2019 - 06/2008
3	GoldIBA 12/2018 - 01/2007
3	Recombinant ProteinsIBA 01/2017 - 11/2003
3	Neutralizing AntibodiesIBA 01/2017 - 09/2015
3	Membrane Proteins (Integral Membrane Proteins)IBA 12/2016 - 09/2008
3	dimethyldioctadecylammonium (dimethyldioctadecylammonium chloride)IBA 06/2014 - 11/2006
3	TrehaloseIBA 06/2014 - 04/2012
2	Opioid Analgesics (Opioids)IBA 01/2022 - 11/2018
2	PolymersIBA 01/2021 - 03/2016
2	InterferonsIBA 01/2020 - 01/2017
2	Immunodominant EpitopesIBA 01/2020 - 08/2009
2	Pharmaceutical PreparationsIBA 01/2020 - 01/2020
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2019 - 10/2018
2	Hemagglutinins (Hemagglutinin)IBA 01/2018 - 08/2011
2	IC31 adjuvantIBA 01/2017 - 05/2008
2	hydroxide ionIBA 04/2015 - 01/2010
2	OvalbuminIBA 06/2014 - 06/2012
2	monophosphoryl lipid AIBA 04/2012 - 11/2006
2	Interleukin-12 (IL 12)IBA 01/2012 - 08/2011
2	Interleukin-6 (Interleukin 6)IBA 01/2012 - 01/2010
2	epidermal growth factor receptor VIIIIBA 02/2009 - 01/2008
2	Tuberculosis VaccinesIBA 06/2008 - 10/2005
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2008 - 10/2007
2	Virulence Factors (Pathogenicity Factors)IBA 05/2006 - 06/2004
1	trametinibIBA 12/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2022
1	glesatinibIBA 12/2022
1	ChitinIBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	InflammasomesIBA 01/2021
1	calpastatinIBA 01/2021

Therapy/Procedure

7	Therapeutics 01/2020 - 05/2006
2	Transplantation 01/2022 - 10/2017
2	Radiotherapy 01/2020 - 11/2014
2	Drug Therapy (Chemotherapy) 01/2017 - 04/2008
2	Aftercare (After-Treatment) 06/2012 - 01/2012
2	Mucosal Administration 01/2007 - 11/2006
1	Perioperative Period 01/2022
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022